2024 Round-Up: PoNS® Takes Big Steps Forward
As the year comes to a close, we’re reflecting on the progress we’ve made and the meaningful impact PoNS® has had on individual lives. Read on for a recap of this year’s highlights!
Amplifying the voices of people living with MS
- Real-life PoNS users Kerrie Walters and US Veteran Kevin Byrne shared their inspiring stories during Helius Medical webinars designed to help others understand how PoNS Therapy® improves the ability to walk for people with multiple sclerosis (MS)—and helps them get back to doing what they love.
- Kevin was also interviewed by his local news station. Watch now!
Helping US Veterans with MS Get Back In Step With Life
- PoNS is more accessible to veterans than ever, thanks to a new partnership with Lovell Government Services. Now, US Veterans with a valid prescription can access PoNS through the VA and other federally approved healthcare systems. “While clinical results have demonstrated the effectiveness of PoNS Therapy, it’s firsthand accounts like Captain Byrne’s that are the most gratifying,” said Dane Andreeff, President and CEO of Helius, of the impact of this partnership. Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services, agreed, stating, “Veterans have given the best to our country and should have access to the most innovative and effective resources available.”
- We explored more ways to provide better care for veterans at this year’s Federal Small Business Conference in New Orleans. There, we focused on key issues regarding veteran healthcare access, connected with decision-makers, and gained a wealth of knowledge that will help inform our goals for 2025.
Highlighting clinical evidence and neuroplasticity
- The PoNSTEP study delivered promising results:
- 100% of clinical trial participants saw at the minimum a 4-point improvement in Dynamic Gait Index (DGI) scores after 14 weeks of PoNS Therapy, with an average of almost 8 points improvement
- 40% saw an improvement above 8 points
- The PoNSTEP study also demonstrated that adherence is positively linked to outcomes
- 50% of participants (with 85-100% adherence) saw nearly a 7-point improvement
- 74% of participants (with 70% adherence) gained at least a 4-point improvement from baseline to end of treatment
- The PoNSTEP results will also be shared at the upcoming ACTRMS (American Committee for Treatment and Research in Multiple Sclerosis) Forum
- In a conversation with Neurology Live, Helius Medical CMO Dr. Antonella Favit-VanPelt discussed the clinical advantage of PoNS and its neuroplastic effects, noting that one of its greatest strengths is the “empowering” user experience. “PoNS has the advantage of being readily accessible,” she said. “[It] allows a great deal of autonomy and independence.” Read the full interview here
- We connected with physical therapists across the country at this year’s APTA CSM conference in Boston. There, board-certified neurological and vestibular specialist Dr. Naseem Chatiwala discussed the success she has seen when incorporating PoNS Therapy into her practice. She further detailed her clinical experience with PoNS on the MSing Link podcast. “Stability has improved in all three of my patients [who are using PoNS],” she shared. “The biggest change we have seen is in ambulation.”
Listen here
Individual results and experiences may vary. Talk to your doctor to see if PoNS is right for you.
If you or someone you love is struggling with walking ability due to MS, PoNS can be used to Get Back In Step With Life.
